Cataract formation is prevented by administration of verapamil to diabetic rats

The purpose of the present study was to examine the effects on cataractogenesis of daily sc administration of the Ca2+ antagonist drug verapamil to diabetic rats. Streptozotocin-induced diabetic rats were given verapamil half-way through the 8-week experimental period or during the full 8 weeks of d...

Full description

Saved in:
Bibliographic Details
Published inEndocrinology (Philadelphia) Vol. 125; no. 2; p. 730
Main Authors Pierce, G N, Afzal, N, Kroeger, E A, Lockwood, M K, Kutryk, M J, Eckhert, C D, Dhalla, N S
Format Journal Article
LanguageEnglish
Published United States 01.08.1989
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The purpose of the present study was to examine the effects on cataractogenesis of daily sc administration of the Ca2+ antagonist drug verapamil to diabetic rats. Streptozotocin-induced diabetic rats were given verapamil half-way through the 8-week experimental period or during the full 8 weeks of diabetes. Verapamil administration had no effect on the high blood glucose values, low circulating insulin levels, or elevated triglyceride and cholesterol concentrations in the diabetic rats. Untreated diabetic rats had a 90% incidence of cataracts. Four weeks of verapamil administration reduced this incidence to 41%, and a full 8 weeks of drug treatment further lowered the incidence to 20%. Diltiazem, another Ca2+ antagonist, lowered the incidence of cataracts in the diabetic rats to a similar extent. Verapamil administration to the diabetic animals also partially protected against the presence of retinal microangiopathy in the diabetic animals. Lenticular hydration and lipid accumulation were only indirectly related to cataractogenesis in the diabetic rats and its protection by verapamil treatment. Lenticular electrolyte imbalance, particularly Ca2+, in the diabetic animals was closely correlated with cataract formation, and verapamil significantly reduced the alterations in these ion concentrations. The present results demonstrate the efficacy of verapamil as a protective agent against cataractogenesis and some retinal damage in diabetic animals. Most importantly, this occurs in the absence of any change in the glycemic status of the diabetic animals. The findings strongly support a role for lenticular Ca2+ imbalance in cataract development in diabetes and provide initial evidence to suggest its clinical use in the diabetic population at risk for blindness.
AbstractList The purpose of the present study was to examine the effects on cataractogenesis of daily sc administration of the Ca2+ antagonist drug verapamil to diabetic rats. Streptozotocin-induced diabetic rats were given verapamil half-way through the 8-week experimental period or during the full 8 weeks of diabetes. Verapamil administration had no effect on the high blood glucose values, low circulating insulin levels, or elevated triglyceride and cholesterol concentrations in the diabetic rats. Untreated diabetic rats had a 90% incidence of cataracts. Four weeks of verapamil administration reduced this incidence to 41%, and a full 8 weeks of drug treatment further lowered the incidence to 20%. Diltiazem, another Ca2+ antagonist, lowered the incidence of cataracts in the diabetic rats to a similar extent. Verapamil administration to the diabetic animals also partially protected against the presence of retinal microangiopathy in the diabetic animals. Lenticular hydration and lipid accumulation were only indirectly related to cataractogenesis in the diabetic rats and its protection by verapamil treatment. Lenticular electrolyte imbalance, particularly Ca2+, in the diabetic animals was closely correlated with cataract formation, and verapamil significantly reduced the alterations in these ion concentrations. The present results demonstrate the efficacy of verapamil as a protective agent against cataractogenesis and some retinal damage in diabetic animals. Most importantly, this occurs in the absence of any change in the glycemic status of the diabetic animals. The findings strongly support a role for lenticular Ca2+ imbalance in cataract development in diabetes and provide initial evidence to suggest its clinical use in the diabetic population at risk for blindness.
Author Pierce, G N
Kutryk, M J
Afzal, N
Kroeger, E A
Lockwood, M K
Eckhert, C D
Dhalla, N S
Author_xml – sequence: 1
  givenname: G N
  surname: Pierce
  fullname: Pierce, G N
  organization: Division of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada
– sequence: 2
  givenname: N
  surname: Afzal
  fullname: Afzal, N
– sequence: 3
  givenname: E A
  surname: Kroeger
  fullname: Kroeger, E A
– sequence: 4
  givenname: M K
  surname: Lockwood
  fullname: Lockwood, M K
– sequence: 5
  givenname: M J
  surname: Kutryk
  fullname: Kutryk, M J
– sequence: 6
  givenname: C D
  surname: Eckhert
  fullname: Eckhert, C D
– sequence: 7
  givenname: N S
  surname: Dhalla
  fullname: Dhalla, N S
BackLink https://www.ncbi.nlm.nih.gov/pubmed/2752974$$D View this record in MEDLINE/PubMed
BookMark eNotj8tqwzAUREVJSZ202-4K-gG1uleyZS-L6QsC2bTrIFkSqMSWkdRA_r6GZDUMB4Y5G7Ka4uQIeQT-DAj8xU02MsCaIVOC35AKOlkzBYqvSMU5CKYQ1R3Z5Py7VCmlWJM1qho7JSuy73XRSQ-F-phGXUKcaMh0Tu7kpuIsNWeq7RimkEu64OjpySU96zEcaYnUBm1cCQNdeL4nt14fs3u45pb8vL99959st__46l93bJDQFIYAyysJtQHBueDYthp9DZ4ra4X0ArHjnRqUb6Q0ttNK2MWjscZCa1uBW_J02Z3_zOjsYU5h1Ol8uIrhPyTGUSM
CitedBy_id crossref_primary_10_1016_S0360_3016_98_00458_1
crossref_primary_10_1007_BF00571933
crossref_primary_10_1089_jop_1995_11_527
crossref_primary_10_1016_j_metabol_2004_03_017
crossref_primary_10_3390_cells11071196
crossref_primary_10_1248_bpb_35_866
crossref_primary_10_1016_0024_3205_96_00374_8
crossref_primary_10_1254_jphs_FP0072294
crossref_primary_10_1016_0002_9343_94_90152_X
crossref_primary_10_1016_0168_8227_95_01090_Z
crossref_primary_10_1177_000456329703400211
crossref_primary_10_1371_journal_pone_0064676
crossref_primary_10_1006_exer_1997_0330
crossref_primary_10_1002_cbf_1144
crossref_primary_10_1016_j_ejphar_2021_174061
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1210/endo-125-2-730
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1945-7170
ExternalDocumentID 2752974
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-DZ
-~X
.55
.GJ
.XZ
08P
0R~
18M
1TH
29G
2WC
34G
354
39C
3O-
3V.
4.4
48X
53G
5GY
5RE
5RS
5YH
79B
8F7
AABZA
AACZT
AAIMJ
AAJQQ
AAKAS
AAPGJ
AAPQZ
AAPXW
AARHZ
AAUQX
AAVAP
AAWDT
AAYJJ
ABEFU
ABHFT
ABJNI
ABLJU
ABMNT
ABNHQ
ABPPZ
ABPQP
ABPTD
ABQNK
ABSAR
ABWST
ABXVV
ACFRR
ACGFO
ACGFS
ACIPB
ACIWK
ACPRK
ACUTJ
ADBBV
ADGKP
ADGZP
ADHKW
ADIYS
ADQBN
ADRTK
ADVEK
ADZCM
AELWJ
AEMDU
AENEX
AENZO
AETBJ
AETEA
AEWNT
AFDAS
AFFNX
AFFZL
AFGWE
AFOFC
AFRAH
AFULF
AFXAL
AFYAG
AGINJ
AGKRT
AGMDO
AGQXC
AGUTN
AHMBA
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
APJGH
AQKUS
ARIXL
AVNTJ
BAWUL
BAYMD
BCRHZ
BENPR
BEYMZ
BPHCQ
BSWAC
BTRTY
BVXVI
BYORX
C1A
C45
CDBKE
CGR
CJ0
CS3
CUY
CVF
DAKXR
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
EMOBN
ENERS
F5P
FA8
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
HF~
HZ~
H~9
IAO
IH2
IHR
ITC
J5H
KBUDW
KOP
KQ8
KSI
KSN
L7B
LMP
M5~
MBLQV
MHKGH
MJL
MVM
NLBLG
NOMLY
NOYVH
NPM
NVLIB
O9-
OAUYM
OBH
ODMLO
OFXIZ
OHH
OHT
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
PQQKQ
PROAC
Q-A
REU
ROX
ROZ
TEORI
TJX
TLC
TMA
TR2
TWZ
UPT
VQP
VVN
W2D
W8F
WH7
WHG
WOQ
X52
X7M
XJT
XOL
YBU
YHG
YOC
YQI
YSK
YYP
ZA5
ZCA
ZCG
ZGI
ZKB
ZXP
ZY1
ID FETCH-LOGICAL-c416t-211227415b130030288a2f51f07dd34f3229097c7f644bd9a73d7226dbd18d832
ISSN 0013-7227
IngestDate Thu May 23 22:56:44 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c416t-211227415b130030288a2f51f07dd34f3229097c7f644bd9a73d7226dbd18d832
PMID 2752974
ParticipantIDs pubmed_primary_2752974
PublicationCentury 1900
PublicationDate 1989-08-01
PublicationDateYYYYMMDD 1989-08-01
PublicationDate_xml – month: 08
  year: 1989
  text: 1989-08-01
  day: 01
PublicationDecade 1980
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Endocrinology (Philadelphia)
PublicationTitleAlternate Endocrinology
PublicationYear 1989
SSID ssj0014443
Score 1.4792622
Snippet The purpose of the present study was to examine the effects on cataractogenesis of daily sc administration of the Ca2+ antagonist drug verapamil to diabetic...
SourceID pubmed
SourceType Index Database
StartPage 730
SubjectTerms Animals
Calcium - analysis
Cataract - drug therapy
Cataract - prevention & control
Diabetes Mellitus, Experimental - complications
Diabetes Mellitus, Experimental - pathology
Diabetic Retinopathy - drug therapy
Diabetic Retinopathy - prevention & control
Diltiazem - therapeutic use
Injections
Lens, Crystalline - analysis
Lipids - analysis
Male
Microcirculation - drug effects
Rats
Rats, Inbred Strains
Retina - blood supply
Retina - drug effects
Verapamil - administration & dosage
Verapamil - pharmacology
Verapamil - therapeutic use
Title Cataract formation is prevented by administration of verapamil to diabetic rats
URI https://www.ncbi.nlm.nih.gov/pubmed/2752974
Volume 125
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA6rongRn_gmB_EW6SM17XERRdRVDwreJGkSFbRdtAp68a8702S71hfqpSzNbtjN93V25svMhJANq4EHVgkmuAkYT0PLMmM1y22gdKZzHUoMFHvH2_vn_OAiueh0Xt9lLT1Wait_-bKu5D-owj3AFatk_4BsMyncgNeAL1wBYbj-CuMdWdXtlocliHg-ed91ZXKupWw1x0XX8AkLrlDWQLfTSa_Yxlm6lk6NSl_oEgyKU93RDUXlBVtK9q8xvbaRD05vMDOmVteHuzpd-yJvW_s8h_elufKlNUP59KjE86ldzk_PC65aNilW6UCB8FY1jJmIXI3_lnGGNOMJg1AxaFlaV-PsKRW9s5vCbc58sucQkNbI6pLBhxkEA-03Ah79uxrdSCRR5g78-XHwQ3dtPzJCRkSKBvIYxR6_CcW5T7r0P8_3_MSip_Y3miTjfp4PwUntpJxNkykfXdCuo8oM6Zhilsx1C1mVd890k9b5vjWks2Si59Mq5sjJgEi0IRK9eaANkah6pm0i0dLShki0KumASBSJNE_O93bPdvaZP2mD5eCQVywCrxv7GCUKdzdj8DlTGdkktIHQOuY2xlMBMpELC-4zPMNSxBpWZFsrHaYa_hQWyGhRFmaRUCOMhJBAyFRqrnkI81jLQ5UGQgRK5Etkwa3QZd-1U7n0S7f83cAKmRyybpWMWXh6zRq4gpVarwF7A2KXW8Y
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cataract+formation+is+prevented+by+administration+of+verapamil+to+diabetic+rats&rft.jtitle=Endocrinology+%28Philadelphia%29&rft.au=Pierce%2C+G+N&rft.au=Afzal%2C+N&rft.au=Kroeger%2C+E+A&rft.au=Lockwood%2C+M+K&rft.date=1989-08-01&rft.issn=0013-7227&rft.eissn=1945-7170&rft.volume=125&rft.issue=2&rft.spage=730&rft_id=info:doi/10.1210%2Fendo-125-2-730&rft_id=info%3Apmid%2F2752974&rft_id=info%3Apmid%2F2752974&rft.externalDocID=2752974
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0013-7227&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0013-7227&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0013-7227&client=summon